【1】Nurit Kaiser,Rafael Nesher,Andrei Oprescu,et al.Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic β-cells. British Journal of Pharmacology (2005) 146, 872–881.
【2】孙永金.口服降糖药物研究进展. 现代医药卫生.2006,22(l3):1985-1986.
【3】Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229) , a new anti-diabetic drug, on ATP-sensitive K + channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur-J-Pharmacol, 2001, 431: 119-125.
【4】M Shigeto,M Katsura,M Matsuda,et al.Nateglinide and mitiglinide,but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.J Pharmacol.Exp.Ther,2007,322:1-7.
【5】Frank Reimann, Peter Proks and FrancesM.A shcroft Effects of mitiglinide (S21403) on Kir6.2/SUR1, Kir6.2/SUR2 and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol, 2001, 132:1542-1548.
【6】K Ojima,Y Kiyono,Nippon Yakurigaku Zasshi.Pharmacological and clinical porfile of mitiglinide calcium hydrate(Glufast),a new insulinotropic agent with rapid onset.Nippon Yakurigaku Zasshi,2004,124(4):245~255.
【7】Mori Y, Ojima K, Fuujimori Y,et al.Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine. 2006 Apr;29(2):309-315.
【8】K Misawa,K Ichikawa,K Ojima,et al.Effect of KAD一1229，a nonsulfonylurea hypo一glycemic agent,on plasma glucose and insulin in streptozotocin一induced diabetic dogs.Pharmacol,2001,62(2):65~72.
【9】K Ichikawa,T Yamato,Kojima,et al.Effect of KAD一1229，a novel hypoglycaemic agent,on plasma glucose levels after meal load in type 2 diabetic rats.Clin Exp Phramacol Physiol.2002,29(5-6):423-427.
【10】Landgraf R. Antidiabetic Drug at Every Meal. Mmw Fortsch ritte Medizin, 2000, 142: 29-30.
【11】Carcia GV, Freeman RV, Sup ianoMA, et al. Glucose metabolismin older adults: A study including subjects more than 80 years of age. J AM Geriatr Soc, 1997, 45: 813-817.
【12】陈小勇，彭润涛．江 宇，等．治疗糖尿病新药米格列奈．中国医药情报．2004，10(2)：28．
【13】王广宇，朱旅云，等.米格列奈治疗2型糖尿病临床试验研究.临床内科杂志,2006 Dec 23(12):812-814.
【14】T Yoshihara，N Kumashiro，Y Kanazawa,et al.Therapeutic Efficacy of Mitiglinide Combined with Once Daily Insulin Glargine after Switching from Multiple Daily Insulin Regimen of Aspart Insulin and Glargine in Patients with Type 2 Diabetes Mellitus. Endocrin J,2006,53(1):67-72.
【15】N Kumashiro,T Yoshihara,Y Kanazawa,et al.Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study.Endocrin J,2007,54(1):163-166.
【16】 Maruyama I, Tomiyama Y, Maruyama K,et al.Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. Eur J Pharmacol. 2006 Feb 15;531(1-3):194-200.
【17】Kazuhiko Ogawa, Katsunori Ikewaki, Ikuo Taniguchi, et al.Mitiglinide, a Novel Oral Hypoglycemic Agent, Preserves the Cardioprotective Effect of Ischemic Preconditioning in Isolated Perfused Rat Hearts. Int Heart J，2007，48(3):337~345.
【18】F Gregorio,F Ambrosi,M Boemi,et al.Effects of S21403 on hormone secretion from isolated rat pancreas at different glucose concentrations.Eur J Pharmacol,2002,456(1):141-147.
【19】Assaloni R,Da-Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia, 2005, 48: 1919-1924.
分页:
[ 1 ]
[ 2 ]
